MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy

AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - mdpi.com
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …

[HTML][HTML] p38 MAPKs—roles in skeletal muscle physiology, disease mechanisms, and as potential therapeutic targets

CM Brennan, CP Emerson Jr, J Owens, N Christoforou - JCI insight, 2021 - ncbi.nlm.nih.gov
Abstract p38 MAPKs play a central role in orchestrating the cellular response to stress and
inflammation and in the regulation of myogenesis. Potent inhibitors of p38 MAPKs have …

[HTML][HTML] Virus-induced p38 MAPK activation facilitates viral infection

Y Cheng, F Sun, L Wang, M Gao, Y Xie, Y Sun, H Liu… - Theranostics, 2020 - ncbi.nlm.nih.gov
Rationale: Many viral infections are known to activate the p38 mitogen-activated protein
kinase (MAPK) signaling pathway. However, the role of p38 activation in viral infection and …

Facioscapulohumeral muscular dystrophy: the road to targeted therapies

MS Tihaya, K Mul, J Balog, JC de Greef… - Nature Reviews …, 2023 - nature.com
Advances in the molecular understanding of facioscapulohumeral muscular dystrophy
(FSHD) have revealed that FSHD results from epigenetic de-repression of the DUX4 gene in …

Facioscapulohumeral muscular dystrophy

JM Statland, R Tawil - CONTINUUM: Lifelong Learning in …, 2016 - journals.lww.com
Abstract Purpose of Review: This article describes the clinical characteristics, diagnosis,
molecular pathogenesis, and treatment of facioscapulohumeral muscular dystrophy (FSHD) …

DUX4 role in normal physiology and in FSHD muscular dystrophy

E Mocciaro, V Runfola, P Ghezzi, M Pannese… - Cells, 2021 - mdpi.com
In the last decade, the sequence-specific transcription factor double homeobox 4 (DUX4)
has gone from being an obscure entity to being a key factor in important physiological and …

Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update

T Schätzl, L Kaiser, HP Deigner - Orphanet Journal of Rare Diseases, 2021 - Springer
Whilst a disease-modifying treatment for Facioscapulohumeral muscular dystrophy (FSHD)
does not exist currently, recent advances in complex molecular pathophysiology studies of …

DUX4 signalling in the pathogenesis of facioscapulohumeral muscular dystrophy

KRQ Lim, Q Nguyen, T Yokota - International journal of molecular …, 2020 - mdpi.com
Facioscapulohumeral muscular dystrophy (FSHD) is a disabling inherited muscular disorder
characterized by asymmetric, progressive muscle weakness and degeneration. Patients …

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy

A Greco, R Goossens, B Van Engelen… - Clinical …, 2020 - Wiley Online Library
Facioscapulohumeral muscular dystrophy (FSHD), a common hereditary myopathy, is
caused either by the contraction of the D4Z4 macrosatellite repeat at the distal end of …

Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies

CJ Wong, LH Wang, SD Friedman… - Human molecular …, 2020 - academic.oup.com
Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD)
have led to the discovery of candidate therapeutics, and it is important to identify markers of …